|Bid||0.8810 x 1800|
|Ask||0.8966 x 900|
|Day's Range||0.8800 - 0.9641|
|52 Week Range||0.4800 - 9.1500|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for AFIB
Joining me on today's call is David Roman, chief executive officer and chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call do not relate to matters of historical fact should be considered forward-looking statements.
Acutus Medical Inc (NASDAQ: AFIB) has launched an expanded suite of left-heart access products, including the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device. AcQCross is a transseptal system engineered with an integrated needle and dilator to reduce the multiple exchanges of wires and needles while trying to achieve the proper angle and location on the septum. Related: Acutus Medical Stock Soars On Debt Refinancing, Divestiture Of Left-Heart Acce
Thank you for standing by, and welcome to the Acutus Medical, Inc. first quarter 2022 earnings conference call. Joining me on today's call are Scott Huennekens, chairman of Acutus's board of directors; and David Roman, interim chief executive officer and chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.